Clinical trials: Substance Use Disorders
Alcohol Use Disorder
Contingency Management for Alcohol Use Disorder
Randomized pilot study of a device (smartphone app) that poses non-significant risk to participants and is exempt from Investigational Device Exemption regulations [21 Code of Federal Regulations 812.2(c)
- Trial name
- NCT03701204
- Testing
- DynamiCare Rewards
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- DynamiCare Health
Tobacco Dependence
Single-dose Pharmacokinetics of Oral Nicotine Replacement Products
This is an explorative study comparing new prototypes of Nicotine Replacement Products with Nicorette® gum.
- Trial name
- NCT01228617
- Testing
- Nicotine, Nicotine Gum
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Alcohol Use Disorder
Pilot Evaluation of the Empower Neuromodulation System in AUD Patients
This study evaluates the effects of peripheral nerve stimulation on alcohol craving and consumption in participants with alcohol use disorder (AUD).
- Trial name
- NCT03983317
- Testing
- Empower Neuromodulation System
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Theranova, L.L.C.
Cocaine Use, Cocaine Intoxication
Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)
This is a Phase 2 single-blind, randomized, multicenter study to compare the efficacy and safety of a single dose of TNX-1300 to placebo with usual care in patients with acute cocaine intoxication within the emergency department…
- Conditions
- Cocaine Use, Cocaine Intoxication, Cocaine Toxicity, Cocaine Abuse
- Trial name
- CATALYST (NCT06045793)
- Testing
- TNX-1300 (Injection)
- Where
- 6 sites in United States
- Volunteers
- 3 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Opioid Use Disorders
Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence
Phase III, randomized, double-blind, double-dummy, active-controlled, parallel group multi-center trial, designed to evaluate the non-inferiority of CAM2038 compared to an existing standard of care (SL BPN/NX) in initiation and…
- Trial name
- NCT02651584
- Testing
- CAM2038 SC injection, SL BPN/NX tabs
- Where
- 36 sites in United States
- Volunteers
- 428 people
- Sponsor
- Braeburn Pharmaceuticals